← GPCalc

NICE Menopause & HRT Calculator

NICE NG23 Menopause: identification and management (Nov 2024) · with NG12 bleeding criteria (Apr 2026), TA1143 fezolinetant (Mar 2026) and FSRH contraception advice

Scenario

Patient

Symptoms

Bleeding

Risk factors & conditions

Current treatment

NICE-recommended plan

Enter age and uterus status to see the plan.

Decision support only, based on NICE NG23 with NG12, TA1143, the BNF and FSRH/BMS guidance where NICE is silent (marked as such). It does not replace clinical judgement, the full guidance, the SPC or local formularies. People with complex needs (e.g. breast cancer, VTE, CVD) should be discussed with a menopause specialist.

Quick reference

Diagnosis by age
AgeNICE approach
45 and overDiagnose clinically, without lab tests: perimenopause = vasomotor symptoms + menstrual change; menopause = no period for 12 months (not on hormonal contraception); after hysterectomy, on symptoms (1.3.1). Don't use FSH, AMH, inhibin, oestradiol or ultrasound (1.3.4)
40–45Consider FSH (follicle-stimulating hormone) to confirm menopause if symptomatic, including menstrual change (1.3.6). If periods have stopped, also exclude pregnancy, thyroid disease (TSH – thyroid-stimulating hormone) and raised prolactin (CKS). Early menopause: offer psychological support if distressed (1.2.7)
Under 40Premature ovarian insufficiency (POI): symptoms with no or infrequent periods + raised FSH (follicle-stimulating hormone) on 2 samples 4–6 weeks apart; never a single test; don't routinely use AMH (anti-Müllerian hormone) (1.7.2–1.7.4). Exclude pregnancy, thyroid disease and raised prolactin (CKS). Refer to a menopause or reproductive medicine specialist if the diagnosis is in doubt (1.7.5); consider referral to find a cause and support fertility (1.7.9; CKS); consider DXA bone scan (BMS). Then HRT or combined hormonal contraception until at least 51 (1.7.6)

Don't use FSH in people on combined hormonal contraception or high-dose progestogen (1.3.5).

Choosing HRT
SituationHRT
Total hysterectomyOestrogen-only (1.8.1)
Uterus, periods within last 12 monthsSequential (cyclical) combined*
Uterus, no period for 12 months+Continuous combined*
Uterus + LNG-IUS 52 mgOestrogen; the IUS provides the progestogen (check licence duration)*
Increased VTE risk incl. BMI >30Consider transdermal rather than oral (1.5.27)

*Regimen choice from BMS/CKS practice; NICE says to discuss sequential vs continuous (1.4.2). Use the lowest effective dose (1.8.3). Review at 3 months, then annually (1.9.2).

HRT benefits & risks (NICE summary)
OutcomeCombined HRTOestrogen-only HRT
Life expectancyUnlikely to change (1.6.1)
Breast cancerIncreased; higher with longer use; stays raised ≥10 years after stopping; sequential less than continuousVery little or no increase
Endometrial cancerContinuous: reduced. Sequential: may slightly increase with longer useIncreased if uterus present – hence combined HRT
Ovarian cancerVery slight increase (baseline very low under 60)
VTEOral increases risk; transdermal does not
StrokeOral increases (more with higher dose, longer use, older start); transdermal unlikely to
Coronary heart diseaseNot increased; no increase in CVD mortality
DementiaMay increase if started at 65+Unlikely to increase
Fragility fractureReduced while taking HRT; benefit declines after stopping
Type 2 diabetesNot increased; glucose control generally unaffected

NICE Tables 1 and 2; absolute figures are in the NICE patient discussion aid. Don't offer HRT to prevent CVD or dementia (1.6.4–1.6.5).

Non-hormonal & other options
  • Menopause-specific CBT for vasomotor, mood and sleep symptoms (1.5.2, 1.5.21, 1.5.23)
  • Don't routinely offer SSRIs, SNRIs or clonidine first-line for vasomotor symptoms alone (1.5.3)
  • Fezolinetant: an option for moderate–severe vasomotor symptoms when HRT is unsuitable; not covered for breast or other oestrogen-dependent cancers (TA1143)
  • Testosterone: consider for low sexual desire if HRT alone is ineffective (1.5.24)
  • Vaginal oestrogen for genitourinary symptoms, alone or with systemic HRT; moisturisers/lubricants; prasterone second line; ospemifene if local treatment impractical (1.5.4–1.5.12)
  • Isoflavones, black cohosh, St John's wort: uncertain safety, purity and interactions (1.4.5–1.4.8)
  • Vaginal laser: only within a trial (1.5.19)
Contraception (FSRH)
  • HRT is not a contraceptive (NG23 1.7.7)
  • Contraception is needed until age 55, or until 1 year of amenorrhoea after 50 (2 years if periods stopped before 50) – FSRH
  • LNG-IUS 52 mg gives contraception and the progestogen part of HRT
  • Check eligibility with the UKMEC calculator
Lifestyle advice & patient leaflet
  • Explain what menopause is, the range of symptoms, and that they vary in severity and duration (1.2.1–1.2.2)
  • Bone health advice, discussed at reviews (1.2.4); maintain muscle mass and strength through activity (1.2.5)
  • Discuss contraception (1.2.3) and keeping up with national screening (1.9.1)